| 11/10/2026 3:38 PM | Inhibikase Therapeutics (1750149) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/10/2026 3:28 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/21/2026 3:10 PM | Inhibikase Therapeutics (1750149) Issuer Wasserman Scott M. (2118767) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/21/2026 3:05 PM | Inhibikase Therapeutics (1750149) Issuer Wasserman Scott M. (2118767) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 10/20/2026 3:57 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/08/2026 3:41 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/26/2026 3:05 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 4:19 PM | Inhibikase Therapeutics (1750149) Subject PERCEPTIVE ADVISORS LLC (1224962) Filed by | Form SCHEDULE 13G/A | |
| 08/13/2026 10:49 AM | Inhibikase Therapeutics (1750149) Subject Sands Capital Life Sciences Pulse Fund II, L.P. (1875620) Filed by | Form SCHEDULE 13G/A | |
| 08/11/2026 3:17 PM | Inhibikase Therapeutics (1750149) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2026 3:32 PM | Inhibikase Therapeutics (1750149) Issuer Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for IKT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/31/2026 3:33 PM | Inhibikase Therapeutics (1750149) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13G/A | |
| 07/31/2026 3:05 PM | BERMAN DENNIS N (1273858) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/17/2026 4:52 PM | Inhibikase Therapeutics (1750149) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13G | |
| 07/17/2026 4:54 PM | Inhibikase Therapeutics (1750149) Issuer Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 07/14/2026 7:11 AM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/30/2026 3:05 PM | Inhibikase Therapeutics (1750149) Issuer Munshi Amit (1612551) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2026 3:05 PM | Aurentz Vincent (1657494) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2026 3:05 PM | Bellini Roberto (1802453) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2026 3:05 PM | Inhibikase Therapeutics (1750149) Issuer Kush Arvind (1986806) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2026 3:05 PM | Canner David (2041173) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2026 3:05 PM | BERMAN DENNIS N (1273858) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 5:05 AM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 7:13 PM | ADAR1 Capital Management, LLC (1940272) Filed by Inhibikase Therapeutics (1750149) Subject | Form SCHEDULE 13G/A | |
| 05/15/2026 3:15 PM | Inhibikase Therapeutics (1750149) Subject Trails Edge Capital Partners, LP (2077247) Filed by | Form SCHEDULE 13G/A | |
| 05/12/2026 3:31 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/30/2026 3:05 PM | Inhibikase Therapeutics (1750149) Filer | Form DEF 14A | |
| 04/20/2026 3:05 PM | Inhibikase Therapeutics (1750149) Filer | Form PRE 14A | |
| 04/07/2026 7:09 AM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/26/2026 3:32 PM | Inhibikase Therapeutics (1750149) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/26/2026 3:21 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/24/2026 7:48 PM | Inhibikase Therapeutics (1750149) Issuer Munshi Amit (1612551) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 7:53 PM | Cabell Christopher (1814928) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 7:54 PM | Aurentz Vincent (1657494) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 5:22 PM | ADAR1 Capital Management, LLC (1940272) Filed by Inhibikase Therapeutics (1750149) Subject | Form SCHEDULE 13G/A | |
| 02/17/2026 3:30 PM | Fairmount Funds Management LLC (1802528) Filed by Inhibikase Therapeutics (1750149) Subject | Form SCHEDULE 13G/A | |
| 02/13/2026 10:30 AM | Inhibikase Therapeutics (1750149) Subject Sands Capital Life Sciences Pulse Fund II, L.P. (1875620) Filed by | Form SCHEDULE 13G/A | |
| 01/07/2026 3:18 PM | Inhibikase Therapeutics (1750149) Issuer McIntyre David (1404254) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 3:21 PM | Cabell Christopher (1814928) Reporting Inhibikase Therapeutics (1750149) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 3:23 PM | Inhibikase Therapeutics (1750149) Issuer Iwicki Mark T (1415537) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/31/2025 4:00 PM | Inhibikase Therapeutics (1750149) Subject Trails Edge Capital Partners, LP (2077247) Filed by | Form SCHEDULE 13G | |
The Democrats can’t stop this (Ad) Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency.
His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge.
He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century. Get Porter Stansberry's briefing on Trump's new dollar and the three steps he outlines. |
| 12/19/2025 3:14 PM | Inhibikase Therapeutics (1750149) Filer | Form 424B5 | |
| 12/19/2025 3:17 PM | Inhibikase Therapeutics (1750149) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/24/2025 2:47 PM | Inhibikase Therapeutics (1750149) Issuer Sands Capital Alternatives, LLC (1846444) Reporting Sands Capital Life Sciences Pulse Fund II, L.P. (1875620) Reporting SANDS FRANK M. (1870494) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/21/2025 3:23 PM | Inhibikase Therapeutics (1750149) Filer | Form 424B5 | |
| 11/20/2025 3:35 PM | Inhibikase Therapeutics (1750149) Filer | Form 424B5 | |